Swedbank AB Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Swedbank AB purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 137,400 shares of the biotechnology company’s stock, valued at approximately $16,706,000. Swedbank AB owned approximately 0.14% of Sarepta Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SRPT. Blue Trust Inc. raised its holdings in shares of Sarepta Therapeutics by 56.9% during the 4th quarter. Blue Trust Inc. now owns 891 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 323 shares in the last quarter. PFG Investments LLC raised its stake in shares of Sarepta Therapeutics by 1.2% during the fourth quarter. PFG Investments LLC now owns 26,998 shares of the biotechnology company’s stock worth $3,283,000 after acquiring an additional 324 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of Sarepta Therapeutics by 219.7% in the 4th quarter. Fifth Third Bancorp now owns 1,832 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 1,259 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 23.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 247 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

SRPT has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Raymond James restated an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Robert W. Baird lowered their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $113.72 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company’s fifty day moving average price is $122.80 and its 200-day moving average price is $127.23. The stock has a market cap of $10.86 billion, a PE ratio of 90.98 and a beta of 0.77. Sarepta Therapeutics, Inc. has a 12 month low of $102.15 and a 12 month high of $173.25.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.